Literature DB >> 30345591

Intracameral antibiotics for prophylaxis of postoperative endophthalmitis in Australia: a review.

Lior Lipsky1, Graham Barrett1,2.   

Abstract

Postoperative endophthalmitis is a severe complication which may result in loss of vision. Intracameral antibiotics have been shown to reduce the risk of this complication and are extensively used worldwide, with vancomycin, cefuroxime and moxifloxacin most commonly used. Choices in Australia are currently limited to vancomycin and cefazolin, since cefuroxime and moxifloxacin are not available. Vancomycin has been safely and effectively used in our department for more than two decades. Recent publications have risen concerns regarding the association of haemorrhagic occlusive retinal vasculitis a potentially blinding complication with intracameral vancomycin. This concern has driven us to review the safety and efficacy of currently available antibiotics in the context of Australian practice.
© 2018 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  antibiotics; cataract surgery; endophthalmitis; ophthalmology publication; prophylaxis

Mesh:

Substances:

Year:  2018        PMID: 30345591     DOI: 10.1111/ceo.13419

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

1.  Therapeutic Effects of Intravitreously Administered Bacteriophage in a Mouse Model of Endophthalmitis Caused by Vancomycin-Sensitive or -Resistant Enterococcus faecalis.

Authors:  Tatsuma Kishimoto; Waka Ishida; Ken Fukuda; Isana Nakajima; Takashi Suzuki; Jumpei Uchiyama; Shigenobu Matsuzaki; Daisuke Todokoro; Masanori Daibata; Atsuki Fukushima
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Intraoperative Cefuroxime Irrigation Prophylaxis for Acute-Onset Endophthalmitis After Phacoemulsification Surgery.

Authors:  Xiubin Ma; Lixin Xie; Yusen Huang
Journal:  Infect Drug Resist       Date:  2020-05-18       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.